Phase 2 Head and Neck Cancer Trial, Recruiting NCT06997068 Sponsor: Mayo Clinic Condition: Head and Neck Cancer
Back to Head And Neck Cancer

Phase 2 Head and Neck Cancer Trial, Recruiting

NCT06997068
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are 18 years of age or older
  • You have been diagnosed with head and neck cancer (mouth, throat, voice box, or related areas — including HPV-positive and HPV-negative types) that has come back or spread, confirmed by a tissue biopsy
  • Your cancer can be measured on a scan or detected by other means (such as a visible lump or bone involvement)
  • You have already received standard first-line immunotherapy or chemotherapy-plus-immunotherapy, OR you were unable to receive it or chose not to
  • You are reasonably active and able to care for yourself (confirm with trial site regarding fitness level requirements)
  • Your blood counts, liver function, kidney function, and blood clotting results from within the last 15 days meet certain minimum levels (confirm exact values with trial site)
  • If you could become pregnant, you have had a negative pregnancy test within 8 days before joining
  • You are willing and able to sign a consent form, attend all scheduled visits, and follow the study plan
  • You are able to swallow pills
  • You are able to complete questionnaires on your own or with help

Who may not be able to join:

  • You are currently pregnant or breastfeeding
  • You or your partner could become pregnant and you are unwilling to use reliable contraception during the study
  • You have had a heart attack within the last 6 months
  • You have moderate to severe heart failure, serious heart rhythm problems, or poorly controlled chest pain
  • You have a heart rhythm measurement (QTc) above a certain level, or factors that increase your risk of dangerous heart rhythms (confirm with trial site)
  • You have an active infection that requires treatment
  • You are currently experiencing active bleeding in your stomach or intestines
  • You have a mental health or personal situation that would make it hard to follow the study requirements
  • Your immune system is severely weakened, or you are HIV-positive and currently taking anti-HIV medication (note: HIV-positive patients without signs of a weakened immune system may still be eligible — confirm with trial site)
  • You have active hepatitis B or hepatitis C that is not controlled or treated (certain exceptions may apply — confirm with trial site)
  • You are currently taking part in another clinical trial that is treating your cancer
  • You have another active cancer that currently requires treatment such as radiation, chemotherapy, or immunotherapy (patients on hormone therapy for breast or prostate cancer, or with a second cancer and a life expectancy of 2 or more years, may still be eligible — confirm with trial site)
  • You have another serious illness or condition that the trial doctors believe would make participation unsafe or affect the results

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 5 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Katharine A. Price, MD, Mayo Clinic in Rochester

Phone: 855-776-0015

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Registry
ClinicalTrials.gov
Start date
9 July 2025
Est. completion
30 June 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Rates of provider referral and patient enrollment (Feasibility); Rate of retention (Feasibility); Rate of conversion from virtual to in-person visits (Feasibility)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 5 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov